Reps. John Dingell and Bart Stupak (both D-MI) wrote the FDA to question its use of a pharma PR firm in developing a website about DTC advertising for consumers.
Sen. Herb Kohl (D-WI) said DTC ads for devices should be regulated just as much as those for drugs and called on his colleague in the House, Rep. Bart Stupak (D-MI), to work with him towards that end.
Sen. Herb Kohl said he was “prepared to call for future moratoriums” on DTC ads for new medical devices, citing “real risks and serious complications.”
Obama win could spark regulatory frenzy, says ex-FDA chief counsel
What impact will the presidential election have on advertising regulation? That’s the question that Richard Cooper posed to attendees at the Food and Drug Law Institute’s 20th annual Advertising & Promotion Conference in Washington, DC.
Researches involved in the litigation against Vioxx claim the product’s ADVANTAGE trials were based on marketing objectives rather than scientific rigor.
FDA cracks down on conflicts of interest in committees
A new GAO report finds the FDA incapable of reviewing all drug advertising — including the identification of off-label promotions — due to the quantity of submissions and the variety of materials.